Assembly Biosciences Says Assembly Bio Eligible For Up To $280M In Milestones And Royalties Outside U.S.; GS-1179 Expected To Advance Into Phase 2 Trial For Genital Herpes By End Of 2026; Assembly Bio Expects Cash Runway Into 2029

Benzinga Newsdesk www.benzinga.com Positive 90.8%

Neg 0% Neu 0% Pos 90.8%

Comments

No comments yet. Be the first!